Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. HIV infection is independently associated with a higher concentration of alpha-1 antitrypsin

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Fourth European stroke science workshop

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Persistent disparities in antiretroviral treatment (ART) coverage and virological suppression across Europe, 2004 to 2015

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Uptake of HCV treatment in HIV/HCV coinfected patients across europe in the era of direct-acting antivirals

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Variation in antiretroviral treatment (ART) coverage and virological suppression among three HIV key populations

    Research output: Contribution to journalJournal articleResearchpeer-review

  • A Roen
  • K Laut
  • A Pelchen-Matthews
  • E Borodulina
  • L Caldeira
  • A Clarke
  • B Clotet
  • A d'Arminio Monforte
  • G Fätkenheuer
  • J M Gatell Artigas
  • I Karpov
  • A Kuznetsova
  • G Kyselyova
  • I Mozer-Lisewska
  • F Mulcahy
  • L Ragone
  • A Scherrer
  • V Uzdaviniene
  • L Vandekerckhove
  • V Vannappagari
  • L Ostergaard
  • A Mocroft
  • EuroSIDA study
View graph of relations

OBJECTIVES: Five to eight per cent of HIV-positive individuals initiating abacavir (ABC) experience potentially fatal hypersensitivity reactions (HSRs). We sought to describe the proportion of individuals initiating ABC and to describe the incidence and factors associated with HSR among those prescribed ABC.

METHODS: We calculated the proportion of EuroSIDA individuals receiving ABC-based combination antiretroviral therapy (cART) among those receiving cART after 1 January 2009. Poisson regression was used to identify demographic, and current clinical and laboratory factors associated with ABC utilization and discontinuation.

RESULTS: Between 2009 and 2016, of 10 076 individuals receiving cART, 3472 (34%) had ever received ABC-based cART. Temporal trends of ABC utilization were also heterogeneous, with 28% using ABC in 2009, dropping to 26% in 2010 and increasing to 31% in 2016, and varied across regions and over time. Poisson models showed lower ABC utilization in older individuals, and in those with higher CD4 cell counts, higher cART lines, and prior AIDS. Higher ABC utilization was associated with higher HIV RNA and poor renal function, and was more common in Central-East and Eastern Europe and lowest during 2014. During 779 person-years of follow-up (PYFU) in 2139 individuals starting ABC after 1 January 2009, 113 discontinued ABC within 6 weeks of initiation for any reason [incidence rate (IR) 14.5 (95% confidence interval (CI) 12.1, 17.5) per 100 PYFU], 13 because of reported HSR [IR 0.3 (95% CI 0.1, 1.0) per 100 PYFU] and 35 because of reported HSR/any toxicity [IR 4.5 (95% CI 3.2, 6.3) per 100 PYFU]. There were no factors significantly associated with ABC discontinuation because of reported HSR/any toxicity.

CONCLUSIONS: ABC remains commonly used across Europe and the incidence of discontinuation because of reported HSR was low in our study population.

Original languageEnglish
JournalHIV Medicine
Pages (from-to)252-260
ISSN1464-2662
DOIs
Publication statusPublished - 2018

    Research areas

  • Journal Article

ID: 52585086